Recurrence of urothelial disease is the main determinant of survival among patients who undergo endoscopic treatment for upper tract urothelial carcinoma (UTUC), new research presented at the American Urological Association’s 2023 Annual Meeting in Chicago, Illinois, suggests.
The finding is from a study of 215 patients (60% male; mean age 73.5 years) who underwent 392 endoscopic procedures for UTUC. Recurrence was the single predictor of mortality, independently increasing the risk by approximately 2.3-fold in adjusted analyses, Jaime Herrera-Caceres, MD, of Penn State Health in Hershey, Pennsylvania, and colleagues reported in a poster presentation.
Of the 215 patients, 61% had a history of smoking, 55% had a history of bladder cancer, and 4.3% had undergone cystectomy. In addition, 57% of patients had lesions larger than 1 cm and 16.5% had high-grade tumors. Surgeons used an intracavitary approach in 30% of endoscopic treatments. Post-procedure recurrence occurred in 57.9% of patients, and 14.5% underwent nephroureterectomy.
A total of 97 patients died after a mean follow-up of 33 months.
Herrera-Caceres J, Egner T, Labbate C, et al. Overall survival after endoscopic treatment of UTUC. Presented at: AUA 2023, April 28-May 1, Chicago, Illinois. Abstract MP58-20.